Welcome to GLOW, the Global nLPHL One Working Group. We are an international collaborative research group conducting rigorous scientific study of nodular lymphocyte-predominant Hodgkin lymphoma (nLPHL).
WHY STUDY NLPHL?
No current standard of care exists today for pediatric or adult patients.
Variability of NLPHL treatment and surveillance (Lo and Major et al., 2022) often results in over-treatment of patients, causing avoidable late effects that decrease survivors’ quality of life and wasting limited healthcare resources.
No current frontline trial exists to study NLPHL.
NLPHL has been separated and excluded from all frontline trials of classical Hodgkin lymphoma since the shift to precision medicine and targeted therapeutic agents.
There has been no previous global study to investigate NLPHL.
Because of the rarity of NLPHL, individual institutions and national consortia have been unable to power meaningful studies to discover better NLPHL treatment strategies.
WE ARE WORKING TO REMEDY THIS
GLOW has a multifaceted strategy to study nLPHL across all ages through retrospective clinical study, pathologic case review, translational biologic experiments, and patient-reported outcomes studies. We are currently planning an international clinical trial in order to optimize the treatment of nLPHL for every adult and child.
Our mission is to optimize the diagnosis and treatment of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) through international collaboration that will allow for rigorous scientific investigations of this rare disease.